Literature DB >> 21804067

Enhancement by LDL of transfer of L-4F and oxidized lipids to HDL in C57BL/6J mice and human plasma.

David Meriwether1, Satoshi Imaizumi, Victor Grijalva, Greg Hough, Ladan Vakili, G M Anantharamaiah, Robin Farias-Eisner, Mohamad Navab, Alan M Fogelman, Srinivasa T Reddy, Ishaiahu Shechter.   

Abstract

The apoA-I mimetic peptide L-4F [(Ac-D-W-F-K-A-F-Y-D-K-V-A-E-K-F-K-E-A-F-NH2) synthesized from all L-amino acids] has shown potential for the treatment of a variety of diseases. Here, we demonstrate that LDL promotes association between L-4F and HDL. A 2- to 3-fold greater association of L-4F with human HDL was observed in the presence of human LDL as compared with HDL by itself. This association further increased when LDL was supplemented with the oxidized lipid 15S-hydroxy-5Z, 8Z, 11Z, 13E-eicosatetraenoic acid (15HETE). Additionally, L-4F significantly (P = 0.02) promoted the transfer of 15HETE from LDL to HDL. The transfer of L-4F from LDL to HDL was demonstrated both in vitro and in C57BL/6J mice. L-4F, injected into C57BL/6J mice, associated rapidly with HDL and was then cleared quickly from the circulation. Similarly, L-4F loaded onto human HDL and injected into C57BL/6J mice was cleared quickly with T(1/2) = 23.6 min. This was accompanied by a decline in human apoA-I with little or no effect on the mouse apoA-I. Based on these results, we propose that i) LDL promotes the association of L-4F with HDL and ii) in the presence of L-4F, oxidized lipids in LDL are rapidly transferred to HDL allowing these oxidized lipids to be acted upon by HDL-associated enzymes and/or cleared from the circulation.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21804067      PMCID: PMC3173006          DOI: 10.1194/jlr.M016741

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  54 in total

1.  The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum.

Authors:  R J HAVEL; H A EDER; J H BRAGDON
Journal:  J Clin Invest       Date:  1955-09       Impact factor: 14.808

2.  ApoA-I mimetic peptides with differing ability to inhibit atherosclerosis also exhibit differences in their interactions with membrane bilayers.

Authors:  Shaila P Handattu; David W Garber; Dawn C Horn; Donald W Hughes; Bob Berno; Alex D Bain; Vinod K Mishra; Mayakonda N Palgunachari; Geeta Datta; G M Anantharamaiah; Richard M Epand
Journal:  J Biol Chem       Date:  2006-11-16       Impact factor: 5.157

3.  A role for oxidized phospholipids in atherosclerosis.

Authors:  Judith A Berliner; Andrew D Watson
Journal:  N Engl J Med       Date:  2005-07-07       Impact factor: 91.245

4.  Intestine may be a major site of action for the apoA-I mimetic peptide 4F whether administered subcutaneously or orally.

Authors:  Mohamad Navab; Srinivasa T Reddy; G M Anantharamaiah; Satoshi Imaizumi; Greg Hough; Susan Hama; Alan M Fogelman
Journal:  J Lipid Res       Date:  2011-03-28       Impact factor: 5.922

5.  D-4F decreases brain arteriole inflammation and improves cognitive performance in LDL receptor-null mice on a Western diet.

Authors:  Georgette M Buga; Joy S Frank; Giuliano A Mottino; Michael Hendizadeh; Ashkan Hakhamian; Jan H Tillisch; Srinivasa T Reddy; Mohamad Navab; G M Anantharamaiah; Louis J Ignarro; Alan M Fogelman
Journal:  J Lipid Res       Date:  2006-07-11       Impact factor: 5.922

Review 6.  Apolipoprotein A-I mimetic peptides.

Authors:  Mohamad Navab; G M Anantharamaiah; Srinivasa T Reddy; Susan Hama; Greg Hough; Victor R Grijalva; Nicholas Yu; Benjamin J Ansell; Geeta Datta; David W Garber; Alan M Fogelman
Journal:  Arterioscler Thromb Vasc Biol       Date:  2005-04-14       Impact factor: 8.311

7.  Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: step 1.

Authors:  M Navab; S Y Hama; C J Cooke; G M Anantharamaiah; M Chaddha; L Jin; G Subbanagounder; K F Faull; S T Reddy; N E Miller; A M Fogelman
Journal:  J Lipid Res       Date:  2000-09       Impact factor: 5.922

Review 8.  Structural requirements for antioxidative and anti-inflammatory properties of apolipoprotein A-I mimetic peptides.

Authors:  G M Anantharamaiah; Vinod K Mishra; David W Garber; Geeta Datta; Shaila P Handattu; Mayakonda N Palgunachari; Manjula Chaddha; Mohamad Navab; Srinivasa T Reddy; Jere P Segrest; Alan M Fogelman
Journal:  J Lipid Res       Date:  2007-06-14       Impact factor: 5.922

9.  Only the two end helixes of eight tandem amphipathic helical domains of human apo A-I have significant lipid affinity. Implications for HDL assembly.

Authors:  M N Palgunachari; V K Mishra; S Lund-Katz; M C Phillips; S O Adeyeye; S Alluri; G M Anantharamaiah; J P Segrest
Journal:  Arterioscler Thromb Vasc Biol       Date:  1996-02       Impact factor: 8.311

10.  Intestinal ABCA1 directly contributes to HDL biogenesis in vivo.

Authors:  Liam R Brunham; Janine K Kruit; Jahangir Iqbal; Catherine Fievet; Jenelle M Timmins; Terry D Pape; Bryan A Coburn; Nagat Bissada; Bart Staels; Albert K Groen; M Mahmood Hussain; John S Parks; Folkert Kuipers; Michael R Hayden
Journal:  J Clin Invest       Date:  2006-03-16       Impact factor: 14.808

View more
  12 in total

1.  D-4F-mediated reduction in metabolites of arachidonic and linoleic acids in the small intestine is associated with decreased inflammation in low-density lipoprotein receptor-null mice.

Authors:  Mohamad Navab; Srinivasa T Reddy; G M Anantharamaiah; Greg Hough; Georgette M Buga; Jan Danciger; Alan M Fogelman
Journal:  J Lipid Res       Date:  2011-12-13       Impact factor: 5.922

2.  An apoA-I mimetic peptibody generates HDL-like particles and increases alpha-1 HDL subfraction in mice.

Authors:  Shu-Chen Lu; Larissa Atangan; Ki Won Kim; Michelle M Chen; Renee Komorowski; Carolyn Chu; Joon Han; Sylvia Hu; Wei Gu; Murielle Véniant; Minghan Wang
Journal:  J Lipid Res       Date:  2012-01-27       Impact factor: 5.922

3.  Transintestinal transport of the anti-inflammatory drug 4F and the modulation of transintestinal cholesterol efflux.

Authors:  David Meriwether; Dawoud Sulaiman; Alan Wagner; Victor Grijalva; Izumi Kaji; Kevin J Williams; Liqing Yu; Spencer Fogelman; Carmen Volpe; Steven J Bensinger; G M Anantharamaiah; Ishaiahu Shechter; Alan M Fogelman; Srinivasa T Reddy
Journal:  J Lipid Res       Date:  2016-05-19       Impact factor: 5.922

4.  Apolipoprotein A-I mimetic peptide 4F blocks sphingomyelinase-induced LDL aggregation.

Authors:  Su Duy Nguyen; Matti Javanainen; Sami Rissanen; Hongxia Zhao; Jenni Huusko; Annukka M Kivelä; Seppo Ylä-Herttuala; Mohamad Navab; Alan M Fogelman; Ilpo Vattulainen; Petri T Kovanen; Katariina Öörni
Journal:  J Lipid Res       Date:  2015-04-10       Impact factor: 5.922

Review 5.  High-density lipoprotein mimetics: promises and challenges.

Authors:  Dmitri Sviridov; Alan T Remaley
Journal:  Biochem J       Date:  2015-12-15       Impact factor: 3.857

6.  Preservation of biological function despite oxidative modification of the apolipoprotein A-I mimetic peptide 4F.

Authors:  C Roger White; Geeta Datta; Amanda K W Buck; Manjula Chaddha; Gautam Reddy; Landon Wilson; Mayakonda N Palgunachari; Mohammad Abbasi; G M Anantharamaiah
Journal:  J Lipid Res       Date:  2012-05-15       Impact factor: 5.922

7.  L-4F inhibits lipopolysaccharide-mediated activation of primary human neutrophils.

Authors:  Oleg F Sharifov; Xin Xu; Amit Gaggar; Edlue M Tabengwa; C Roger White; Mayakonda N Palgunachari; G M Anantharamaiah; Himanshu Gupta
Journal:  Inflammation       Date:  2014-10       Impact factor: 4.092

8.  Apolipoprotein A-I mimetics mitigate intestinal inflammation in COX2-dependent inflammatory bowel disease model.

Authors:  David Meriwether; Dawoud Sulaiman; Carmen Volpe; Anna Dorfman; Victor Grijalva; Nasrin Dorreh; R Sergio Solorzano-Vargas; Jifang Wang; Ellen O'Connor; Jeremy Papesh; Muriel Larauche; Hannah Trost; Mayakonda N Palgunachari; G M Anantharamaiah; Harvey R Herschman; Martin G Martin; Alan M Fogelman; Srinivasa T Reddy
Journal:  J Clin Invest       Date:  2019-06-11       Impact factor: 19.456

9.  A mechanistic paradigm for broad-spectrum antivirals that target virus-cell fusion.

Authors:  Frederic Vigant; Jihye Lee; Axel Hollmann; Lukas B Tanner; Zeynep Akyol Ataman; Tatyana Yun; Guanghou Shui; Hector C Aguilar; Dong Zhang; David Meriwether; Gleyder Roman-Sosa; Lindsey R Robinson; Terry L Juelich; Hubert Buczkowski; Sunwen Chou; Miguel A R B Castanho; Mike C Wolf; Jennifer K Smith; Ashley Banyard; Margaret Kielian; Srinivasa Reddy; Markus R Wenk; Matthias Selke; Nuno C Santos; Alexander N Freiberg; Michael E Jung; Benhur Lee
Journal:  PLoS Pathog       Date:  2013-04-18       Impact factor: 6.823

10.  An apolipoprotein A-I mimetic peptide designed with a reductionist approach stimulates reverse cholesterol transport and reduces atherosclerosis in mice.

Authors:  Michael Ditiatkovski; Wilissa D'Souza; Rajitha Kesani; Jaye Chin-Dusting; Judy B de Haan; Alan Remaley; Dmitri Sviridov
Journal:  PLoS One       Date:  2013-07-09       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.